Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 86

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 86
---
 due to the recognition of A$3.6 million
in R& D tax incentives for the fiscal 2024, and a decrease in the loss on movement in contingent consideration of A$4.8 million for
the year.

Comparison of Our Results for the Year ended June 30, 2024 with
the Year ended June 30, 2023

For results of operations for the years ended June 30, 2024 and 2023,
together with the changes in those items in dollars and as a percentage and the related discussions on these results, refer to Results
of Operations within “ Item 5. A Operating Results” in our Annual Report on Form 20-F/A (Amendment No.2) for the year ended
June 30, 2024, filed with the SEC on December 5, 2024.

Off-Balance Sheet Arrangements

During fiscal years 2025 and
2024, we did not have any unconsolidated entities such as structured finance or special purpose entities that can be used to facilitate
off-balance sheet arrangements.

Tabular Disclosure of Contractual Obligations

As of June 30, 2025, our contractual obligations
were as set forth below:

                                   Payments Due by Period                                                                                                   
                                   Total                                       Less than                     Between                           Between      
  Trade and other payables                                      9,340,993                     9,340,993                         -                           
  Other financial liabilities                                  32,098,324                     1,363,259                         2,363,259                   

Contingent liabilities

We had significant contingent liabilities outstanding as of June 30, 2025, that related to the potential milestone
payments under several license agreements. For details, please see
Note 13 to our financial statements for fiscal year 2025.

Capital commitments

We did not have any material capital expenditure
commitments as of June 30, 2025.

B. Liquidity and Capital Resources

Since our inception, our operations
have mainly been financed through the issuance of equity securities. Additional funding has come through interest earned from cash in
interest earning accounts.

Capital Requirements

As of June 30, 2025, we had
cash and cash equivalents of A$29,116,835. We anticipate that our current cash will be sufficient to fund our operations through fiscal
2026. However, our forecast of the period of time through which our financial resources will be adequate to support our